Zhejiang Jiuzhou Pharm Co Ltd

SHG:603456 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.04 Billion
CN¥14.96 Billion CNY
Market Cap Rank
#6858 Global
#1101 in China
Share Price
CN¥16.82
Change (1 day)
-0.41%
52-Week Range
CN¥12.55 - CN¥21.87
All Time High
CN¥60.21
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Zhejiang Jiuzhou Pharmaceutical Co., Ltd operates as contract development and manufacturing organization (CDMO) company in China and internationally. The company offers small molecule, drug product, and peptide CDMO services. It also involved in business related to supporting the development of new drugs and pharmaceuticals. It serves global pharmaceutical companies, biotechnology companies, and … Read more

Zhejiang Jiuzhou Pharm Co Ltd (603456) - Net Assets

Latest net assets as of June 2025: CN¥8.78 Billion CNY

Based on the latest financial reports, Zhejiang Jiuzhou Pharm Co Ltd (603456) has net assets worth CN¥8.78 Billion CNY as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.96 Billion) and total liabilities (CN¥2.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥8.78 Billion
% of Total Assets 80.14%
Annual Growth Rate 25.26%
5-Year Change 178.98%
10-Year Change 242.23%
Growth Volatility 32.33

Zhejiang Jiuzhou Pharm Co Ltd - Net Assets Trend (2011–2024)

This chart illustrates how Zhejiang Jiuzhou Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Zhejiang Jiuzhou Pharm Co Ltd (2011–2024)

The table below shows the annual net assets of Zhejiang Jiuzhou Pharm Co Ltd from 2011 to 2024.

Year Net Assets Change
2024-12-31 CN¥8.61 Billion +0.90%
2023-12-31 CN¥8.53 Billion +58.86%
2022-12-31 CN¥5.37 Billion +17.35%
2021-12-31 CN¥4.58 Billion +48.31%
2020-12-31 CN¥3.09 Billion +7.97%
2019-12-31 CN¥2.86 Billion +2.89%
2018-12-31 CN¥2.78 Billion +3.63%
2017-12-31 CN¥2.68 Billion +4.44%
2016-12-31 CN¥2.57 Billion +2.03%
2015-12-31 CN¥2.52 Billion +58.90%
2014-12-31 CN¥1.58 Billion +114.90%
2013-12-31 CN¥736.75 Million +23.39%
2012-12-31 CN¥597.08 Million +29.65%
2011-12-31 CN¥460.54 Million --

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang Jiuzhou Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1221.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥3.03 Billion 35.52%
Other Components CN¥5.50 Billion 64.48%
Total Equity CN¥8.54 Billion 100.00%

Zhejiang Jiuzhou Pharm Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang Jiuzhou Pharm Co Ltd ranked by their market capitalization.

Company Market Cap
Carel Industries S.p.A.
LSE:0YQA
 		$1.12 Billion
Beijing Qianjing Landscape Co
SHG:603778
 		$1.12 Billion
SYLVAMO CORP. DL 100
F:88L
 		$1.12 Billion
Everi Holdings Inc
NYSE:EVRI
 		$1.12 Billion
Willdan Group Inc
NASDAQ:WLDN
 		$1.12 Billion
The South Indian Bank Limited
NSE:SOUTHBANK
 		$1.12 Billion
NPK International Inc.
NYSE:NPKI
 		$1.12 Billion
Evotec SE
PINK:EVOTF
 		$1.12 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang Jiuzhou Pharm Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 8,461,133,056 to 8,536,673,817, a change of 75,540,761 (0.9%).
  • Net income of 606,096,351 contributed positively to equity growth.
  • Dividend payments of 471,296,198 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥606.10 Million +7.1%
Dividends Paid CN¥471.30 Million -5.52%
Other Changes CN¥-59.26 Million -0.69%
Total Change CN¥- 0.89%

Book Value vs Market Value Analysis

This analysis compares Zhejiang Jiuzhou Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.76x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 5.07x to 1.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 CN¥3.32 CN¥16.82 x
2018-12-31 CN¥3.44 CN¥16.82 x
2019-12-31 CN¥3.54 CN¥16.82 x
2020-12-31 CN¥3.83 CN¥16.82 x
2021-12-31 CN¥5.50 CN¥16.82 x
2022-12-31 CN¥6.35 CN¥16.82 x
2023-12-31 CN¥9.41 CN¥16.82 x
2024-12-31 CN¥9.54 CN¥16.82 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang Jiuzhou Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 7.10%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 11.74%
  • • Asset Turnover: 0.46x
  • • Equity Multiplier: 1.30x
  • Recent ROE (7.10%) is below the historical average (12.46%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 25.63% 12.52% 0.84x 2.44x CN¥71.37 Million
2012 22.99% 11.92% 0.85x 2.27x CN¥77.00 Million
2013 22.69% 12.69% 0.84x 2.12x CN¥92.98 Million
2014 8.43% 10.97% 0.55x 1.40x CN¥-24.80 Million
2015 7.95% 13.85% 0.43x 1.33x CN¥-51.50 Million
2016 4.35% 6.74% 0.55x 1.17x CN¥-144.53 Million
2017 5.52% 8.59% 0.55x 1.17x CN¥-119.91 Million
2018 5.67% 8.44% 0.56x 1.19x CN¥-120.21 Million
2019 8.33% 11.79% 0.43x 1.64x CN¥-47.67 Million
2020 12.34% 14.38% 0.53x 1.62x CN¥72.26 Million
2021 13.85% 15.60% 0.58x 1.54x CN¥176.19 Million
2022 17.39% 16.91% 0.69x 1.49x CN¥391.27 Million
2023 12.21% 18.71% 0.51x 1.28x CN¥187.14 Million
2024 7.10% 11.74% 0.46x 1.30x CN¥-247.57 Million

Industry Comparison

This section compares Zhejiang Jiuzhou Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Zhejiang Jiuzhou Pharm Co Ltd (603456) CN¥8.78 Billion 25.63% 0.25x $1.12 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million